Nektar Therapeutics (NKTR) Highlights Data from First-in-Human Phase 1a Study on Novel T Regulatory Cell Stimulator, NKTR-358
Go back to Nektar Therapeutics (NKTR) Highlights Data from First-in-Human Phase 1a Study on Novel T Regulatory Cell Stimulator, NKTR-358| Nektar Therapeutics (NASDAQ: NKTR) | Delayed: 66.84 -0.26 (0.39%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $67.10 | 52 Week High | $19.98 | |||
| Open | $68.53 | 52 Week Low | $10.52 | |||
| Day High | $69.84 | P/E | N/A | |||
| Day Low | $66.71 | EPS | $-1.45 | |||
| Volume | 766,904 | |||||
